Quick answer: Ambien (zolpidem) and Belsomra (suvorexant) are both prescription insomnia medicines and both are Schedule IV controlled substances, but they work in opposite ways. Ambien pushes the brain’s “brake” (GABA) harder, while Belsomra releases the brain’s “accelerator” by blocking orexin, a wake-promoting chemical. In practice, that difference shapes how each is dosed, what side effects are most distinctive, and which warnings appear on the label. Neither is automatically better. The right choice depends on your sleep pattern, your other medicines, your health history, and cost and access.
If you have been told that your insomnia may need medication, you may have run into both names. Ambien has been around since the early 1990s and is the household name. Belsomra arrived in 2014 as the first of a newer group called dual orexin receptor antagonists (DORAs). This article compares the two on how they work, how well they help, what can go wrong, and what to ask your prescriber. It is educational only and doesn’t replace a medical evaluation.
The Brake and the Accelerator: Two Ways to Reach Sleep
The simplest way to understand this comparison is to picture your brain as a car. Staying awake is like pressing the accelerator. Falling asleep means easing off the accelerator, pressing the brake, or both.
Ambien Presses the Brake
Zolpidem enhances GABA, the main inhibitory chemical in the nervous system. By boosting the “slow down” signal, it quiets brain activity broadly, which helps you fall asleep. Because GABA is involved in alertness, coordination, and memory, a strong dose can also dull reaction time and interfere with forming memories. That is why Ambien’s label includes warnings about next-morning impairment and complex sleep behaviors.
Belsomra Eases Off the Accelerator
Orexin (also called hypocretin) is a chemical made in a small part of the brain that helps keep you awake and stabilizes the wake state. Suvorexant blocks both orexin receptors, so the wake signal weakens and sleep becomes easier to reach and maintain. It does not directly boost GABA. That makes it a different kind of sedation rather than a “milder” or “stronger” one, and it is the reason Belsomra has distinct side effects such as sleep paralysis and vivid dreams.
Why the Difference Matters in Real Life
- Different side effects. Orexin blockers have some effects tied to the sleep-wake switch itself, like sleep paralysis and cataplexy-like symptoms, while GABA-type drugs have the well-known complex sleep behavior warning.
- Different drug interactions. Belsomra is cleared mainly through a liver enzyme (CYP3A), so certain other medicines can raise or lower its levels.
- Different dosing logic. Belsomra has a minimum sleep window of at least 7 hours; Ambien’s label asks for 7 to 8 hours.
Side-by-Side Snapshot
| Feature | Ambien (zolpidem) | Belsomra (suvorexant) |
|---|---|---|
| Drug class | GABA-A modulator (“Z-drug”) | Dual orexin receptor antagonist (DORA) |
| First FDA approval | 1992 | 2014 |
| Approved for | Insomnia (the immediate-release form is aimed at trouble falling asleep; the extended-release form also targets staying asleep) | Insomnia with difficulty falling asleep and/or staying asleep |
| Controlled substance? | Yes, Schedule IV | Yes, Schedule IV |
| Typical labeled dosing | 5 mg or 10 mg immediate-release (5 mg recommended for women); 6.25 mg or 12.5 mg extended-release | 10 mg recommended; may be increased up to 20 mg; 5 mg with certain interacting medicines |
| Timing | Immediately before bed, with 7 to 8 hours available for sleep | Within 30 minutes of bed, with at least 7 hours before waking |
| Boxed warning | Yes (complex sleep behaviors, added 2019) | No boxed warning, but the label warns about next-day impairment, complex sleep behaviors, sleep paralysis, hallucinations, and cataplexy-like symptoms |
| Generic availability | Widely available as a generic | Brand-name product; ask your pharmacist about current generic availability |
| Contraindication highlights | Prior complex sleep behavior with zolpidem, eszopiclone, or zaleplon | Narcolepsy |
How Well Does Each One Work?
Sleep medicine is full of modest numbers. In clinical trials, both drug types beat placebo, but the gap is usually measured in minutes rather than hours, and individual responses vary widely. Keep that in mind as you read what follows.
What the Trials Showed for Belsomra
When the FDA approved Belsomra in 2014, the company reported that in clinical trials it was better than placebo for how long it took to fall asleep and for staying asleep, measured both by overnight sleep studies and by patients’ own estimates. The most common side effect in trials was sleepiness.
What the Evidence Says About Zolpidem
Zolpidem has a much longer research record. It has repeatedly been shown to shorten the time to fall asleep and, in some forms, to improve sleep continuity. Its long history is also why we know so much about its downsides.
What the Sleep Medicine Guidelines Say
The American Academy of Sleep Medicine (AASM) published a clinical practice guideline on drug treatment of chronic insomnia in 2017. It made weak recommendations in favor of several drugs, including zolpidem for sleep onset and sleep maintenance insomnia and suvorexant for sleep maintenance insomnia. The guideline did not rank one drug above another, because there weren’t enough head-to-head comparison studies. It also stressed that cognitive behavioral therapy for insomnia (CBT-I) should be offered as the primary treatment for chronic insomnia. Guidelines are updated over time, so ask your clinician whether newer recommendations apply to you.
The Honest Bottom Line
Because direct, large-scale comparisons are limited, nobody can say with confidence that one will work better for you. A practical approach is to match the medicine to the problem you have (falling asleep versus staying asleep), review safety factors, and give the choice a fair trial with follow-up.
Falling Asleep vs. Staying Asleep: Which Problem Do You Have?
Insomnia comes in several patterns, and the pattern influences which medicine a prescriber may consider.
Trouble Falling Asleep (Sleep-Onset Insomnia)
You lie awake for a long time before drifting off. Immediate-release zolpidem was designed with this pattern in mind, and its quick onset is part of its appeal. Belsomra also lists sleep onset in its indication, though it is often discussed in connection with sleep maintenance.
Trouble Staying Asleep (Sleep-Maintenance Insomnia)
You fall asleep fine but wake up repeatedly, or wake very early and can’t get back to sleep. Belsomra’s 7-hour minimum window and its way of stabilizing sleep make it a common choice in this category. Extended-release zolpidem is also designed for this pattern, although the FDA specifically warns people not to drive the day after taking Ambien CR. See our guide to Ambien next-day drowsiness and driving.
Mixed Patterns
Many people have both, which is part of why a sleep log is so useful. Spend two weeks writing down bedtime, estimated time to fall asleep, awakenings, final wake time, and how you felt the next day. Take it to your appointment.
Side Effects and Safety: What Distinguishes Each Drug
Both medicines can cause drowsiness, dizziness, and headaches, and both can impair you the next day. The differences are in the details.
Warnings That Stand Out for Ambien
- Boxed warning for complex sleep behaviors. In 2019 the FDA required a boxed warning after reviewing 66 cases, including 20 deaths, of people who did things like sleepwalk or drive while not fully awake. People typically did not remember the events. See Ambien and memory loss.
- Next-morning impairment. The FDA lowered the recommended starting dose for women in 2013 because they clear zolpidem more slowly. See why women get a lower Ambien dose.
- Memory effects. Anterograde amnesia while awake after a dose is a recognized issue.
Warnings That Stand Out for Belsomra
- Sleep paralysis, hallucinations, and cataplexy-like symptoms. The label describes these as effects of the orexin system being dampened, and the risk of cataplexy-like symptoms rises with dose. Sleep paralysis is the experience of being awake but unable to move, and hypnagogic or hypnopompic hallucinations occur while falling asleep or waking.
- Narcolepsy is a contraindication. People with narcolepsy already have an orexin problem, so blocking orexin is not appropriate.
- Daytime wakefulness. The label notes that Belsomra can impair daytime wakefulness, and that central nervous system depressant effects may last for a time after stopping.
- Dose-related risk. Higher doses increase side effects. In trials, doses above the recommended range had similar effectiveness but significantly more adverse reactions.
- Mood. The label advises watching for worsening depression or suicidal thoughts, as with other hypnotics.
- Sex and body size. Reference sources note that drug exposure is higher in women than men and in people with obesity, so prescribers consider this before raising the dose. It’s a parallel to the Ambien dosing story.
Shared Risks
- Next-day impairment and driving. The FDA’s reminder is that all insomnia medicines can impair driving and alertness the morning after use, even if you feel awake. The risk rises with higher doses, with less than a full night of sleep, and when combined with other sedating substances.
- Complex sleep behaviors. The Belsomra label includes sleep-driving and other complex behaviors among its warnings, and says the risk increases with dose, with other central nervous system depressants, and with alcohol.
- Alcohol and other sedatives. Both are best taken without alcohol, opioids, benzodiazepines, or sedating antihistamines. See why doubling up on sleep products is risky.
- Breathing. People with sleep apnea or lung disease should discuss both with a clinician. The Belsomra label notes it was not studied in people with severe sleep apnea or severe COPD.
- Dependence. Both are Schedule IV, meaning they have potential for misuse and dependence, though the risk is generally considered lower than for older sedatives.
Drug Interactions: Where Belsomra Needs Extra Care
Ambien interacts mostly through added sedation. Belsomra has an additional layer because it is processed by the liver enzyme CYP3A.
| Situation | Ambien | Belsomra |
|---|---|---|
| Alcohol | Avoid; increases sedation and risk of complex sleep behaviors | Avoid; increases next-day impairment and complex behavior risk |
| Opioids, benzodiazepines, other sedatives | Additive sedation; use only under clinician guidance | Additive sedation; dose reduction may be considered |
| Strong CYP3A inhibitors (some antifungals and antibiotics, for example) | Can alter levels; discuss with pharmacist | Not recommended |
| Moderate CYP3A inhibitors | Review with pharmacist | Recommended dose is 5 mg, possibly raised to 10 mg if needed |
| Strong CYP3A inducers | May lower effect; review | May reduce effectiveness; generally not advised |
| Digoxin | No special note on the label | Digoxin levels may need monitoring |
| Severe liver impairment | Lower dosing is recommended | Not recommended |
The practical takeaway is simple: give your prescriber and pharmacist a complete list of everything you take, including supplements and over-the-counter products. A “brown-bag review,” where you bring in all your bottles, catches problems that memory alone misses.
Timing, Meals, and Daily Practicalities
With Food or Without
Both medicines can take longer to work if taken with or soon after a meal. Belsomra’s prescribing information notes that a high-fat meal can delay the time to effect by roughly an hour and a half. If you eat late, that can leave you lying awake and tempted to take extra, which is the wrong response.
Setting the Sleep Window
Both labels ask for a protected sleep window of roughly seven hours or more. If you take either medicine and then have to be up in four or five hours, you are working against the instructions. For more on timing, read how many hours to sleep after taking Ambien.
How Long to Use It
Belsomra’s label advises re-evaluating if insomnia persists after 7 to 10 days, since persistent insomnia may point to another condition. Many clinicians apply the same logic to Ambien. Sleep medicines generally work best as short-term tools alongside CBT-I and other changes.
Cost and Access
This is where the two often diverge in everyday life. Zolpidem is available as an inexpensive generic at most pharmacies. Belsomra has historically been a brand-name product, which can mean higher out-of-pocket costs, and some insurers require prior authorization or a trial of other drugs first. Availability and pricing change, so check with your pharmacy and insurer for current information, and ask your prescriber whether manufacturer savings programs or alternatives apply to you.
Who Might Consider Which? A Conversation Guide
This section is meant to help you frame a discussion, not to choose for you.
Situations Where a Prescriber May Lean Toward Zolpidem
- You mainly struggle to fall asleep
- Cost or insurance coverage is a major factor
- You take medicines that interact with CYP3A, which could complicate Belsomra
- You have no personal history of complex sleep behaviors
Situations Where a Prescriber May Lean Toward an Orexin Antagonist
- You mainly wake during the night or too early
- You have had memory gaps or concerns about GABA-type sedatives (though a prescriber must still weigh all risks)
- You want a different mechanism after a poor experience with a Z-drug
Situations Where Either May Be a Poor Fit
- You can’t protect a full night’s sleep window
- You regularly drink alcohol or use other sedatives
- You must drive or operate machinery early in the morning
- You are pregnant or planning pregnancy (see our overview of Ambien in pregnancy)
- You have narcolepsy (Belsomra), or a history of complex sleep behaviors with a Z-drug (Ambien and related drugs)
Other Options on the Menu
Ambien and Belsomra are two of many choices. Depending on your situation, your clinician may also discuss:
- CBT-I. A structured, evidence-based program that treats the thoughts and habits that sustain insomnia. It is considered the primary treatment for chronic insomnia and has no drug interactions.
- Other orexin antagonists. Newer DORAs have joined Belsomra on the market. Ask your prescriber whether they apply to you.
- Other Z-drugs. Compare Ambien vs. Lunesta and Sonata vs. Ambien. Remember they share the boxed warning.
- Melatonin-receptor agonists. See Rozerem vs. Ambien.
- Sedating antidepressants. Sometimes used off-label. Read our comparison of Ambien vs. trazodone.
- Lifestyle approaches. See our guide to natural remedies for deep sleep.
Questions to Bring to Your Appointment
- Is my insomnia mainly about falling asleep, staying asleep, or both?
- Could another condition, such as sleep apnea, restless legs, pain, anxiety, or depression, be driving it?
- What is the lowest effective dose for me, given my sex, age, weight, and liver function?
- Do any of my current medicines or supplements interact with this one?
- What should I do the next day if I feel groggy, and when is it safe to drive?
- How long should I plan to use this, and how will we decide whether to stop?
- What will it cost, and are there alternatives if my insurance doesn’t cover it?
- Can I start CBT-I alongside medication?
What the First Week Often Looks Like
Starting any sleep medicine is easier when you know what’s typical and what’s a red flag. The following is a general picture, not a promise, because individual responses vary.
The First Night
With either drug, prepare for bed first: brush your teeth, lock up, set your alarm, and put your phone down. Then take the dose and get into bed. Many people feel sleepy within the first hour, though Belsomra’s effect can take longer to build, particularly if you’ve eaten recently. Resist the urge to take a second dose if you’re still awake after an hour or two. Extra doses are a common route to a rough morning and are not what the labels recommend.
The First Morning
Give yourself time. Notice whether you feel heavy, foggy, or uncoordinated, and whether you can follow a conversation easily. If you feel off, skip driving and let your prescriber know. People who are sensitive to a drug often find out on day one.
The First Week
Keep a simple log: time of dose, time you fell asleep, awakenings, final wake time, and how you felt the next day. Also note any unusual experiences, such as vivid dreams, a sense of being awake but unable to move, strange visual impressions when drifting off, or gaps in memory. These notes help your prescriber decide whether the dose, the timing, or the drug itself needs to change. If insomnia persists after 7 to 10 days, the Belsomra label advises re-evaluating for another underlying condition, and the same practical logic applies to any sleep medicine.
Red Flags That Mean Call Your Prescriber
- Any sleepwalking, sleep-eating, sleep-driving, or activity you don’t remember
- Episodes of being awake but unable to move, or frightening hallucinations while falling asleep or waking
- A sudden feeling of weakness or collapse triggered by strong emotions, which may point to cataplexy-like symptoms
- New or worsening depression, hopelessness, or thoughts of self-harm
- Marked daytime sleepiness that makes work or driving unsafe
Five Myths About Ambien and Belsomra
Myth 1: “A newer drug must be safer.”
Newer isn’t a safety rating. Belsomra doesn’t carry a boxed warning, but it has its own distinct warnings and a shorter track record in the general population. Ambien’s longer history is part of why its risks are so well mapped.
Myth 2: “Because it isn’t a benzodiazepine, there’s no dependence risk.”
Neither Ambien nor Belsomra is a benzodiazepine, but both are Schedule IV controlled substances. That classification reflects recognized potential for misuse and dependence, even if the risk is generally considered lower than with older sedatives.
Myth 3: “If I feel fine, I’m fine to drive.”
The FDA has specifically warned that people can be impaired the morning after taking an insomnia medicine without feeling drowsy. Belsomra’s label also notes that the risk of next-day impairment is higher with less than a full night of sleep remaining and with higher doses.
Myth 4: “A higher dose will work better.”
For Belsomra, trials of doses above the recommended range showed similar effectiveness with significantly more side effects. For zolpidem, the FDA’s 2013 dose changes were based on the idea that lower doses can work for many people while leaving less drug in the system the next day. Using the lowest effective dose is a consistent theme.
Myth 5: “I can take it whenever I wake up in the night.”
Both medicines assume you have a long window of sleep ahead. Taking a dose at 3 a.m. with a 6 a.m. alarm shortens the window and sets up a groggy, risky morning. If middle-of-the-night waking is your main issue, raise it with your prescriber so the plan fits the problem.
Frequently Asked Questions
Is Belsomra stronger than Ambien?
“Stronger” isn’t a useful measure here. They work through different mechanisms and have different side-effect profiles. Neither has been shown in large head-to-head studies to be clearly better for everyone, so choice depends on the individual.
Is Belsomra safer than Ambien?
Belsomra does not carry a boxed warning, while Ambien does, but both have significant safety information on their labels, including next-day impairment and complex sleep behaviors. Belsomra also has distinct risks, such as sleep paralysis and cataplexy-like symptoms. “Safer” depends on your own health and history.
Is Belsomra addictive?
Belsomra is a Schedule IV controlled substance, which means it has potential for abuse and dependence. Zolpidem is also Schedule IV. Talk with your prescriber about your personal risk factors, including any history of substance use.
Can I switch from Ambien to Belsomra on my own?
No. Switching should be supervised by a prescriber, who will consider your dose, how long you have taken zolpidem, your other medicines, and the plan for tapering.
Do either of them cause next-day drowsiness?
Yes. The FDA reminds the public that all insomnia medicines can impair driving and alertness the morning after use, even when you feel fully awake. Risk rises with higher doses and shorter sleep time.
Can I take either one with alcohol?
It is not recommended. Alcohol adds to sedation and raises the risk of impairment and complex sleep behaviors with both medicines.
Which one works faster?
Immediate-release zolpidem is known for quick onset. Belsomra’s labeling notes that the median time to maximum effect is about two hours on an empty stomach, which can feel slower. Individual responses differ, and a heavy meal can delay either.
What if neither works?
Persistent insomnia after 7 to 10 days of treatment is a signal to re-evaluate for underlying causes. Contact your prescriber rather than increasing the dose yourself.
Key Takeaways
- Ambien boosts the brain’s GABA “brake.” Belsomra blocks orexin, the “accelerator.”
- Both are Schedule IV and both can cause next-day impairment, so driving the morning after needs caution.
- Ambien carries an FDA boxed warning for complex sleep behaviors. Belsomra has no boxed warning but has its own warnings, including sleep paralysis and cataplexy-like symptoms, and is contraindicated in narcolepsy.
- Belsomra has important CYP3A drug interactions and is not recommended with strong inhibitors.
- Guidelines make weak recommendations for both and don’t rank them. CBT-I is the primary treatment for chronic insomnia.
- Cost and access often differ. Ask your pharmacist and insurer.
Sources and Further Reading
- U.S. Food and Drug Administration: Belsomra (suvorexant) prescribing information
- U.S. Food and Drug Administration: Boxed Warning for complex sleep behaviors with certain insomnia medicines
- American Academy of Sleep Medicine: Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults (2017)
- MedlinePlus: Zolpidem
Medical disclaimer: This content is for general education only and does not replace professional medical advice, diagnosis, or treatment. Talk with your doctor or pharmacist before starting, changing, or stopping any medicine. If you or someone else is in an emergency, call your local emergency number right away.
